Biotech Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Pharmaceutical executives discuss funding, clinical trials in shareholder letter
June 6th, 2005
Symbollon Pharmaceuticals, Inc. (SYMBA) announced that its executive officers, Jack H. Kessler, chief executive officer and Paul C. Desjourdy, president, issued Letter to Shareholders. Following are exerpts: With the recent announcement of our corporate partnership with Bioaccelerate Holdings, we now have the resources necessary to complete the clinical development of IoGen. For Symbollon's shareholders, this is the event that has been long anticipated and should be warmly received. The finances were the missing piece that had been delaying the start of our planned phase 3 pivotal clinical trials. The results from the first phase 3 pivotal trial should be available in...
Source: Biotech Business Week (2005-06-06)
|
